Trial Profile
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Recaticimab (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Aug 2022 Status changed from recruiting to completed.
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record